Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin DeJesus

Showing results (81-90 of 154) with videos related to

Pageof 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2006
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysisAnton L Pozniak, Joel E Gallant, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled TrialJoseph C Gathe, Edwin Dejesus, Moti N Ramgopal, et al.
HIV Clinical Trials|June 15, 2010
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires, Benjamin Young, Edwin DeJesus, et al.
The New England Journal of Medicine|January 20, 2006
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVJoel E Gallant, Edwin DeJesus, José R Arribas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adultsEdwin DeJesus, Gisela Herrera, Eugenio Teofilo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 17, 2015
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 ResultsJoel E Gallant, Ellen Koenig, Jaime F Andrade-Villanueva, et al.
HIV Clinical Trials|December 13, 2006
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infectionPeter Ruane, Joseph Lang, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 10, 2009
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patientsEdwin Dejesus, Benjamin Young, Javier O Morales-Ramirez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJose R Arribas, Anton L Pozniak, Joel E Gallant, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
Pageof 16

Showing results (81-90 of 154) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2006
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysisAnton L Pozniak, Joel E Gallant, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled TrialJoseph C Gathe, Edwin Dejesus, Moti N Ramgopal, et al.
HIV Clinical Trials|June 15, 2010
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires, Benjamin Young, Edwin DeJesus, et al.
The New England Journal of Medicine|January 20, 2006
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVJoel E Gallant, Edwin DeJesus, José R Arribas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adultsEdwin DeJesus, Gisela Herrera, Eugenio Teofilo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 17, 2015
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 ResultsJoel E Gallant, Ellen Koenig, Jaime F Andrade-Villanueva, et al.
HIV Clinical Trials|December 13, 2006
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infectionPeter Ruane, Joseph Lang, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 10, 2009
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patientsEdwin Dejesus, Benjamin Young, Javier O Morales-Ramirez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJose R Arribas, Anton L Pozniak, Joel E Gallant, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
Pageof 16